6-Ketoprostaglandin F1 alpha and thromboxane B2 in isolated, blood-perfused lungs from monocrotaline pyrrole-treated rats.
Monocrotaline pyrrole (MCTP) causes pulmonary vascular injury and pulmonary hypertension in rats. Although the mechanism by which MCTP causes pulmonary hypertension is unknown, vasoconstriction may play a role. Thromboxane (Tx) A2 is a vasoconstrictor released from platelets and other blood cells. Following treatment with MCTP in vivo, the release of stable metabolites of TxA2 and prostacyclin [TxB2 and 6-keto prostaglandin F1 alpha (6-keto-PGF1 alpha), respectively] was determined in isolated lungs perfused with blood. Early in the development of pulmonary hypertension, the concentrations of TxB2 and 6-keto-PGF1 alpha in the effluent plasma of lungs from treated rats were not different from control rats. When pulmonary hypertension was well established, the concentration of TxB2 was higher in the effluent plasma of lungs from MCTP-treated rats, although the concentration of 6-keto-PGF1 alpha was not affected by treatment.
Ganey
P E
PE
Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824.
Roth
R A
RA
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000818:Animals; D006976:Hypertension, Pulmonary / Q000139:chemically induced; D008168:Lung / Q000098:blood supply*; D008297:Male; D016686:Monocrotaline / Q000031:analogs & derivatives*; D011763:Pyrrolizidine Alkaloids / Q000633:toxicity*; D051381:Rats; D013929:Thromboxane B2 / Q000097:blood*
D011763:Pyrrolizidine Alkaloids; C014114:monocrotaline pyrrole; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D016686:Monocrotaline